Covance worked on all of the top 50 best-selling drugs available today through its full spectrum of nonclinical, clinical and commercialization services.
Covance is a top contract research organization, dedicated to advancing healthcare and delivering Solutions Made Real®
With precision delivery of the largest volume of drug development data on the planet, we can help you identify new approaches and anticipate tomorrow’s challenges. Learn more about our history and services.
Virtual Clinic Tour
Go inside our Madison Clinical Research Unit
On-campus radioanalysis means faster results and deep insights into drug metabolism. Learn more by touring our Madison CRU.
The diabetic heart: A focus on heart failure recording now available
Hear an insightful discussion on how certain molecular classes impact CV outcomes for patients with type 2 diabetes along with strategies for testing new therapeutic, paradigm-modifying treatment modalities.
Rare Disease and Orphan Drugs: accelerate complex studies globally
A range of individual approaches can be integrated to accelerate your progress of complex rare disease studies across the world. Learn how to address key development challenges.
End-to-end drug & diagnostic development support for a new immuno-oncology agent
Find out how Covance/LabCorp helped a prominent pharmaceutical company enable a faster, more effective launch of their immuno-oncology drug.
Implementing basket/bucket and umbrella designs: What you need to know for global oncology trials | May 8, 2017
The biosimilars landscape: What all developers need to know recording now available
The regulatory pathway for developing biosimilars in the U.S. is still considered a new frontier. View this webinar as we discuss the key clinical issues sponsors face when navigating today’s regulatory environment.
Immuno-oncology and the role of biomarkers, companion and complementary diagnostics
Learn more about how the use of a variety of biomarkers, companion diagnostics (CDx) and complementary diagnostics has powered the recent evolution of immunotherapies and their potential applications.
Precision medicine in immuno-oncology
Great strides have been made in the discovery and validation of biomarkers in drug development.
Analytical methods for bioanalysis
Check out our recently updated nonproprietary assay list featuring more than 330 compounds.
Are your economic models delivering?
Transform economic models into highly engaging communication tools.
Meet Covance Market Access at Asembia Specialty Pharmacy Summit 2017, Booth 711
How do YOU measure success? Experience Forward Thinking With Covance Market Access Booth 711, #Asembia 17
Phase I cGMP drug manufacture at the CRU: three big benefits
Using a cGMP pharmacy at your CRU for Phase I drug manufacturing yields benefits in quality and safety, timeline reduction and cost efficiency.
What matters to investigators
Recent study shows lab preferences make a difference in trial participation.
Early Phase Development Solutions
Want to reduce your early development timeline by 30%?
Find out how from Pete Sausen, PhD, vice president, early phase development solutions
Leverage new technological advances to accelerate HIV vaccine development
Read more about the challenges confronting the realization of an effective HIV-1 vaccine along with new solutions.
Have you visited the NASH Education Center?
We’re pleased to announce the launch of the NASH Education Center. Access the latest thoughts from experts through webinars, case studies, blogs, info sheets and scientific articles.
SpecimINSIGHTTM Case Study
Actionable consent data leads to no-go decision in five days before initiating costly Phase III trials, saving client an estimated $100M.
When a potentially market-limiting severe adverse reaction appeared in Phase I and II trials for an early stage Alzheimer’s disease drug development program, the client was able to quickly ensure consent for additional testing to properly determine genetic association. This actionable insight also prompted the client to discontinue trials on the initial compound and pivot to a backup compound.